Indeed, monitoring Flii phosphorylation may be a useful biomarker of breast cancer prognosis as higher Ulk1 activity and p-Flii Ser64 correlates well with improved clinical outcomes in patients, while higher levels of Akt activity and p-Flii Ser436 negatively correlated with a good breast cancer prognosis (He et al., 2018). Here, FLII is linked to breast carcinoma.